Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy by Bosch, S.L. (Steven) et al.
Clinicopathological characteristics predict lymph node
metastases in ypT0-2 rectal cancer after chemoradiotherapy
Steven L Bosch,1 Thomas A Vermeer,2 Nicholas P West,3 Hendrik A M Swellengrebel,4
Corrie A M Marijnen,5 Annemieke Cats,4 Cornelis Verhoef,6 Ineke van Lijnschoten,7
Johannes H W de Wilt,8 Harm J Rutten2,9 & Iris D Nagtegaal1
1Department of Pathology, Radboud University Medical Centre, Nijmegen, 2Department of Surgery, Catharina Hospital
Eindhoven, Eindhoven, the Netherlands, 3Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology,
St James’s University Hospital, University of Leeds, Leeds, UK, 4Department of Gastroenterology and Hepatology,
Netherlands Cancer Institute, Amsterdam, 5Department of Radiotherapy, Leids University Medical Centre, Leiden,
6Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, 7Pathology and Medical Microbiology, Eindhoven,
8Department of Surgery, Radboud University Medical Centre, Nijmegen, and 9Department of Surgery, Maastricht
University Medical Centre, Maastricht, the Netherlands
Date of submission 16 March 2016
Accepted for publication 4 June 2016
Published online Article Accepted 6 June 2016
Bosch S L, Vermeer T A, West N P, Swellengrebel H A M, Marijnen C A M, Cats A, Verhoef C, van Lijnschoten I,
de Wilt J H W, Rutten H J & Nagtegaal I D
(2016) Histopathology. DOI: 10.1111/his.13008
Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer
after chemoradiotherapy
Aims: Changes in rectal cancer treatment include
increasing emphasis on organ preservation. Local exci-
sion after chemoradiotherapy (CRT) for rectal cancer
with excellent clinical response reduces morbidity and
mortality compared to total mesorectal excision,
although residual lymph node metastases (LNM) may
cause local recurrence. Our aim is to identify clinico-
pathological factors predicting the presence of residual
LNM in rectal cancer patients with ypT0-2 tumours
after neoadjuvant CRT. These risk factors may help to
select patients who can be spared radical surgery with-
out compromising oncological outcomes.
Methods and results: Rectal cancer patients with
ypT0-2 tumours after CRT and radical resection from
five centres treated between June 1999 and February
2012 were included. Histopathology was reviewed
extensively. Clinicopathological characteristics and
their association with residual LNM were investigated.
Of 657 consecutive CRT-treated rectal cancer patients
210 with ypT0-2 disease were included. Residual
nodal disease was found in 44 cases (21.0%). Indepen-
dent predictors of LNM were clinical nodal involve-
ment (cN+) [odds ratio (OR): 2.79, 95% confidence
interval (CI): 1.04–7.48, P = 0.042], high-grade
histopathology assessed in the post-CRT resection spec-
imen (OR: 6.46, 95% CI: 1.23–34.02, P = 0.028) and
residual tumour diameter (RTD) ≥10 mm (OR: 2.54,
95% CI: 1.06–6.09, P = 0.036). An algorithm com-
bining these factors stratified patients adequately
according to LNM risk, independently of ypT category.
Conclusions: Clinical nodal involvement, high-grade
histopathology and RTD ≥10 mm are strong and
independent predictors of residual nodal disease in
rectal cancer patients with ypT0-2 tumours after
CRT. Risk stratification based on these factors may
help to identify patients suitable for organ preserving
therapy and should be validated in appropriately
selected populations.
Keywords: chemoradiotherapy, local excision, lymph node metastasis, rectal cancer, ypT
Address for correspondence: S L Bosch, Department of Pathology 824, Radboud University Medical Centre, PO Box 9101, 6500 HB
Nijmegen, the Netherlands. e-mail: steven.bosch@radboudumc.nl
© 2016 John Wiley & Sons Ltd.
Histopathology 2016 DOI: 10.1111/his.13008
Introduction
For locally advanced rectal cancer patients, neoadju-
vant chemoradiotherapy (CRT) consisting of a long
course of radiotherapy and concurrent chemotherapy
followed by total mesorectal excision (TME) is the stan-
dard of care. In 8–24% of patients, neoadjuvant CRT
results in a pathologically complete response (pCR).
These patients have been reported to have an excellent
prognosis, with a 5-year local recurrence rate of 0–2.8
and 83.3–96.9% 5-year disease-free survival.1–3
Radical resection may therefore be superfluous in
selected patients with a good clinical response, and
postoperative morbidity and mortality associated with
TME4,5 could be avoided. Indeed, local recurrence
rates as low as 2.8% and 4.7% have been reported
after a wait-and-see policy for selected patients with a
clinical complete response after CRT.6,7 Nevertheless,
several other studies showed worse outcomes (local
failure rates of 23–60%).8–10 Critics of wait-and-see
point out that criteria for clinical complete response
cited in the literature are not consistent and the evi-
dence is based on highly selected patient groups.11
A full-thickness local excision of the residual
tumour or scar area is an attractive alternative to
wait-and-see, as it removes possible tumour remnants
in the bowel wall. It also provides additional informa-
tion on tumour response and can be used to identify
histopathological risk factors for locally recurrent dis-
ease. Especially for early tumours in the distal part of
the rectum, this strategy has been used successfully
in several small international studies.12 However,
identification of patients who are most likely to bene-
fit from an organ-preserving procedure remains diffi-
cult. A validated set of histopathological risk factors
could help to stratify patients according to local
recurrence risk. Unfortunately, studies on local exci-
sion after CRT are relatively scarce and often lack suf-
ficient numbers of patients to perform a risk
stratification based on histopathological factors.
An alternative approach is to investigate tumour
characteristics associated with residual lymph node
metastases (LNM) in the mesorectal fat of CRT-treated
radical TME specimens. Residual LNM are a potential
source of recurrent disease after local excision and
predictors of LNM in radical resection specimens are
therefore likely to overlap with predictors of local
recurrence after local excision.13,14 In addition,
patients with ypT0-2 rectal cancers after CRT may be
cured with a full-thickness local excision in the
absence of LNM. We therefore investigated possible
predictors of LNM in this group of patients in a multi-
centre study with a central review of histopathology.
Materials and methods
P A T I E N T S A N D S T U D Y D E S I G N
This report describes a pooled analysis of consecutive
rectal cancer patients from five independent centres
with ypT0-2 tumours who received neoadjuvant CRT
followed by TME surgery between June 1999 and
February 2012. Patients considered for CRT either
had evidence of locally advanced disease on preopera-
tive magnetic resonance imaging (MRI) (defined as a
cT4 tumour, a cT3 tumour with threatened mesorec-
tal fascia, a cT3 tumour less than 5 cm from the anal
verge and/or clinical N2 disease), or were otherwise
expected to benefit from CRT during a multidisci-
plinary team meeting (e.g. attempt to preserve the
sphincter in case of a very low T2 tumour). Patients
received an external beam long course of radiother-
apy consisting of 45–50 Gy in 25–28 fractions of
1.8–2.0 Gy and concomitant fluoropyrimidine-based
chemotherapy (with or without oxaliplatin). The clin-
ical target volume included the primary tumour and
the mesorectum with vascular supply, containing the
perirectal, presacral and internal iliac nodes. For this
purely restrospective study ethics approval and
informed consent were not required.
H I S T O P A T H O L O G Y
Routine histopathological evaluation of the resection
specimens was performed in the laboratories of the
participating hospitals according to international
guidelines. For the study, haematoxylin and eosin
(H&E)-stained glass slides or high-resolution digitally
scanned slides as well as histopathology reports were
retrieved and reviewed centrally by a single investiga-
tor (S.L.B.). Difficulties and discrepancies with the
original histopathology report were resolved by con-
sulting an expert gastrointestinal pathologist (I.D.N.).
Cases were excluded if a tumour was determined to
be >ypT2 at review or the histopathological slides
(glass or digital) were unavailable.
The pathological tumour category (ypT) and patho-
logical nodal category (ypN) were evaluated accord-
ing to the TNM classification of malignant tumours, 5th
edition,15 classifying mesorectal tumour deposits of
≥3 mm without evidence of residual lymph node tis-
sue as positive lymph nodes regardless of their con-
tour. Lymph nodes with fibrosis or acellular mucin
lakes, but without viable tumour cells, were consid-
ered to be negative for tumour.
In addition to ypT category the evaluated tumour-
related characteristics included residual tumour
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diameter (RTD), histopathological type and differenti-
ation grade, tumour regression grade (TRG), extent of
tumour necrosis and presence of intramural venous
and lymphatic invasion, perineural growth, budding,
intramural acellular mucinous lakes, calcifications
and peritumoural inflammatory infiltrate.
RTD was defined to be the largest distance between
viable tumour cells in the mucosa, submucosa or
muscularis propria. In the case of tumour regression
with fibrosis and scattered residual tumour cells and
glands, this was the largest distance between individ-
ual tumour cells in the slide. In case tumour cells
were present in two slides, RTD was estimated to be
at least 4 mm, as a block of paraffin-embedded tissue
was estimated to be 4 mm thick. This was at least
8 mm in the case of tumour in three slides, etc. How-
ever, due to the retrospective nature of the study it
was not possible in every case to reproduce reliably
the position of the various tissue blocks and associ-
ated slides relative to each other.
Histopathological type and differentiation grade of
the tumour were assessed in the post-CRT resection
specimen and defined according to WHO 2010
criteria.16 For analytical purposes the cases were
categorized subsequently as having high-grade
histopathology (including poorly differentiated adeno-
carcinoma, undifferentiated carcinoma and signet
ring cell carcinoma) versus other histopathology
(including low-grade adenocarcinoma, mucinous car-
cinoma and pathological complete response).
For TRG, a four-tier grading scale adjusted from
Dworak et al.’s system17 was used. Grades are defined as
follows: grade 1 (no significant response) no fibrosis or
significant fibrosis outgrown by cancer; grade 2 (partial
response) residual cancer outgrown by fibrosis; grade 3
(near-complete response) scattered single tumour cells
or small groups of tumour cells; and grade 4 (pathologi-
cal complete response) no viable tumour cells.
Lymphatic invasion was defined as tumour cells in
a space covered with endothelial cells in the absence
of erythrocytes.18 Venous invasion was diagnosed in
case of tumour within a smooth muscle-lined space
or in an endothelial-lined space with additional fibrin
clots, erythrocytes or both, without erythrocyte
extravasation into the surrounding tissue.18,19 Bud-
ding was defined as presence of at least five foci of up
to five tumour cells in a microscopic field using a
920 objective and evaluated in the area where such
foci are most dense, as described by Ueno et al.20
Grade of tumour necrosis was evaluated according to
Pollheimer et al.21 Acellular mucinous lakes were
determined to be present or absent in the specimen
regardless of tumour cells in the surrounding tissue.
Peritumoural inflammatory infiltrate was determined
to be conspicuous or non-conspicuous, as described
originally in the Jass and Morson classification.22
S T A T I S T I C A L A N A L Y S I S
SPSS version 20 was used to perform the analyses. For
RTD, a receiver operating characteristic curve (ROC)
was created to estimate the cut-off value with optimal
sensitivity and specificity for predicting presence of
LNM. The Mann–Whitney U-test or independent-
samples Kruskal–Wallis test was used for non-para-
metric continuous variables. Categorical variables
were analysed using the v2 test, Mann–Whitney U-test
or independent-samples Kruskal–Wallis test where
appropriate. Factors with a statistically significant
association with LNM or a statistical trend were
included subsequently in a multivariate analysis using
binary logistic regression. A P-value of <0.05 was con-
sidered statistically significant, whereas a P-value of
<0.1 was taken to reflect a trend towards significance.
Results
P A T I E N T S E L E C T I O N
Of 657 consecutive rectal cancer patients from five
centres, who received a long course of CRT and TME,
211 (32.1%) were found to have ypT0-2 disease. One
patient was excluded for lack of histopathological
slides, resulting in 210 patients who were included in
the analysis.
L Y M P H N O D E S
The median number of examined lymph nodes per
patient was 7 (range: 0–39). Residual nodal disease
was found in 44 patients (21.0%). The presence of
LNM was not related to number of lymph nodes sam-
pled in the current population (median number of
examined lymph nodes: 6.5 versus 7.0, respectively,
in patients with versus without residual LNM
(P = 0.439). Of the patients without LNM, 34 showed
signs of tumour regression in lymph nodes, including
acellular mucin in seven cases.
C L I N I C A L C H A R A C T E R I S T I C S
Table 1 shows clinical characteristics and their associa-
tion with presence of LNM. Centre of origin, gender, clin-
ical nodal status (cN) and type of chemotherapy
(fluoropyrimidine only versus capecitabine + oxaliplatin)
were associated significantly with the presence of LNM.
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Table 1. Association of clinical characteristics with residual lymph node metastases
Clinical characteristics
Univariate analysis
Total N = 210
ypN0 ypN+
P-value*n % n %
Total no. of patients 166 79.0 44 21.0
Age (years)‡ 62 (55–68) 59.5 (54.25–69.75) 0.665†
Total number of
examined lymph
nodes‡
7 (4–11) 6.5 (5–12.75) 0.439†
Centre of origin
Centre 1 64 86.5 10 13.5 0.004
Centre 2 27 61.4 17 38.6
Centre 3 21 70.0 9 30.0
Centre 4 6 75.0 2 25.0
Centre 5 48 88.9 6 11.1
Gender
Male 125 83.9 24 16.1 0.007
Female 41 67.2 20 32.8
cT
cT2 7 87.5 1 12.5 0.184†
cT3 99 75.6 32 24.4
cT4 60 85.7 10 14.3
Missing – – 1 –
cN
cN0 60 89.6 7 10.4 0.018
cN+ 98 75.4 32 24.6
Missing 8 – 5 –
Type of chemotherapy
FP only§ 121 75.6 39 24.4 0.033
CAPOX 44 89.8 5 10.2
Missing 1 – – –
Distance to anal verge
<5 cm 92 82.9 19 17.1 0.148
≥5 cm 74 74.7 25 25.3
FP, Fluoropyrimidine; CAPOX, Capecitabine + oxaliplatin; cT, Clinical primary tumour category; cN, Clinical nodal category; ypT, Pathological
primary tumour category after multimodality therapy; ypN, Pathological nodal category after multimodality therapy.
*v2 test is used unless stated otherwise; †Mann–Whitney U-test; ‡median and interquartile range; §Capecitabine (n = 139) or bolus
5FU + leucovorin (n = 21; centres 1 and 4).
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H I S T O P A T H O L O G I C A L T U M O U R
C H A R A C T E R I S T I C S
Changes in classification of histopathological charac-
teristics compared with the original pathology reports
were made in 18 cases after slide review (8.6%). This
included either a T-category downgrade (n = 8),
T-category upgrade (n = 6), N-category downgrade
(n = 1) or N-category upgrade (n = 3). Tumour type
was not changed. Other factors investigated in this
study (e.g. tumour differentiation grade, lymphatic
invasion, TRG, budding, etc.) were not described con-
sistently in the original reports and were therefore
scored primarily at the time of slide review.
Table 2. Association of pathological characteristics with
residual lymph node metastases
Histopathological
characteristics
Univariate analysis
Total N = 210
ypN0 ypN+
P-value*n % n %
Total no. of patients 166 79.0 44 21.0
ypT
ypT0 71 82.6 15 17.4 0.159
ypT1 23 85.2 4 14.8 0.112‡
ypT2 72 74.2 25 25.8
RTD
<10 mm 137 84.0 26 16.0 0.001
≥10 mm 29 61.7 18 38.3
Histopathological type/grade§
Other 163 80.7 39 19.3 0.003
High grade 3 37.5 5 62.5
TRG
pCR 71 82.6 15 17.4 0.769†
Near complete
response
16 66.7 8 33.3
Partial response 76 80.9 18 19.1
No significant
response
3 50.0 3 50.0
Intramural venous invasion
Present 0 – 0 – NA
Absent 166 79.0 44 21.0
Intramural lymphatic channel invasion
Present 11 68.8 5 31.2 0.292
Absent 155 79.9 39 20.1
Intramural perineural growth
Present 0 – 0 – NA
Absent 166 79.0 44 21.0
Budding
Positive 8 61.5 5 38.5 0.117
Negative 155 79.9 39 20.1
Missing 3 – – –
Table 2. (Continued)
Histopathological
characteristics
Univariate analysis
Total N = 210
ypN0 ypN+
P-value*n % n %
Necrosis
Absent 136 81.0 32 19.0 0.117†
Focal (<10%) 17 81.0 4 19.0
Moderate (10–30%) 4 44.4 5 55.6
Extensive (>30%) 8 72.7 3 27.3
Peritumoural inflammatory infiltrate
Conspicuous 27 73.0 10 27.0 0.317
Other 139 80.3 34 19.7
Acellular mucinous lakes
Present 40 75.5 13 24.5 0.459
Absent 126 80.3 31 19.7
Calcification
Present 42 85.7 7 14.3 0.190
Absent 124 77.0 37 23.0
ypT, Pathological primary tumour category after multimodality
therapy; ypN, Pathological nodal category after multimodality ther-
apy; RTD, Residual tumour diameter; TRG, Tumour regression
grade; pCR, Pathological complete response; NA, Not available.
*v2 test is used unless stated otherwise; †Mann–Whitney U-test;
‡ypT0-1 versus ypT2; §Other histopathology includes low-grade
adenocarcinoma (n = 103), mucinous carcinoma (n = 13) and
pathological complete response (n = 86). High grade histopathol-
ogy includes poorly differentiated carcinoma (n = 6), and undiffer-
entiated carcinoma (n = 2).
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Table 2 shows the investigated histopathological
characteristics and the associated LNM rate. The ypT
category did not predict residual nodal disease signifi-
cantly (LNM rate: 17.4%, 14.8% and 25.8% for ypT0,
ypT1 and ypT2, respectively; P = 0.159; and LNM rate
16.8% versus 25.8% for ypT0-1 versus ypT2, respec-
tively; P = 0.112). RTD had a strong association with
presence of LNM. Initial analysis of histopathological
characteristics revealed that mean RTD was signifi-
cantly higher in the ypN+ compared to the ypN0 group
(11.2 and 6.0 mm, respectively, P = 0.022). A ROC
curve showed a RTD of ≥10 mm to be the optimal cut-
off value to predict LNM (sensitivity 43.2%; specificity
81.9%; area under the curve: 0.598). Therefore, this
value was used in the subsequent analyses which
showed LNM in 16.0 versus 38.3% for RTD <10 mm
and ≥10 mm, respectively (P = 0.001).
Of 24 patients with a near-complete response
(TRG 3) there were three with a RTD of ≥10 mm and
one of those showed residual nodal disease.
High-grade histopathology (assessed after neoadju-
vant therapy) was found in eight patients, including
six with poorly differentiated adenocarcinoma and two
with undifferentiated carcinoma. There were no cases
with signet ring cell carcinoma. The majority of
patients had other histopathology (n = 202), including
low-grade adenocarcinoma (n = 103), mucinous carci-
noma (n = 13) and pathological complete response
(n = 86). High-grade histopathology was a statistically
significant predictor for the presence of LNM [LNM rate
62.5 versus 19.3% for high-grade versus other
histopathology, respectively (P = 0.003)].
R O U T I N E H I S T O P A T H O L O G Y D E T A I L S
The median number of tissue blocks available for re-
evaluation per case was 15 (range: 5–52) and the
Table 3. Multivariate analysis
Odds ratio (95% CI) P-value
Centre of origin
Centre 1 1.00 0.426
Centre 2 1.42 (0.37–5.42)
Centre 3 1.32 (0.32–5.46)
Centre 4 0.0 (0.0–∞)
Centre 5 0.48 (0.11–2.07)
Gender
Male 1.00 0.110
Female 1.98 (0.86–4.59)
cN
cN0 1.00 0.042*
cN+ 2.79 (1.04–7.48)
Type of chemotherapy
FP only 1.00 0.298
CAPOX 0.45 (0.10–2.01)
RTD
<10 mm 1.00 0.036*
≥10 mm 2.54 (1.06–6.09)
Histopathology
Other 1.00 0.028*
High grade 6.46 (1.23–34.02)
cN, Clinical nodal category; RTD, Residual tumour diameter; FP,
Fluoropyrimidine; CAPOX, Capecitabine + oxaliplatin; CI, Confi-
dence interval.
*Statistically significant (P < 0.05).
Table 4. Independent risk factors and lymph node metastases rate (LNM) (n = 197^); figures represent patients with LNM
in each subgroup: % (n/N total)
cN0 cN+
Other
histopathology
High grade
histopathology
Other
histopathology
High grade
histopathology
RTD < 10 mm 8.0% (4/50) 100.0% (1/1) RTD < 10 mm 17.8% (18/101)* 25.0% (1/4)†
RTD ≥ 10 mm 6.7% (1/15) 100.0% (1/1) RTD ≥ 10 mm 47.8% (11/23) 100.0% (2/2)
Total 7.7% (5/65) 100.0% (2/2) Total 23.4% (29/124) 50.0% (3/6)
cN, Clinical nodal category; RTD, Residual tumour diameter; ^cases with at least one missing value (n = 13) were excluded; *P = 0.002 for
RTD < 10 mm versus RTD ≥ 10 mm; †P = 0.083 for RTD < 10 mm versus RTD ≥ 10 mm.
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median number of blocks from the tumour area was
six (range: 2–43). The proportion of cases in which
the entire tumour area was embedded could not be
determined reliably retrospectively, as this was not
described consistently in the original reports. Addi-
tional tumour area blocks were embedded in 23 cases
(11.0%) that lacked residual viable tumour in the ini-
tial slides, and this included 14 patients with ypT0
(16.3%). Three additional levels from the tumour
blocks were cut in five cases (2.4%), including two
cases with ypT0 (2.3%). Immunohistochemistry with
cytokeratins was performed in 12 cases (5.7%),
including five5 patients (5.8%) with ypT0.
M U L T I V A R I A T E A N A L Y S I S
Factors with a statistically significant association with
residual nodal disease or a statistical trend were
included in a multivariate analysis (Table 3). Inde-
pendent predictive value was shown for clinical nodal
involvement [odds ratio (OR): 2.79, 95% confidence
interval (CI): 1.04–7.48 for cN+ versus cN0;
P = 0.042], RTD ≥10 mm (OR: 2.54, 95% CI 1.06–
6.09 for RTD ≥10 versus <10 mm; P = 0.036) and
high-grade histopathology (OR: 6.46, 95% CI: 1.23–
34.02 for high-grade versus other histopathology;
P = 0.028). Centre of origin, gender and type of
chemotherapy did not show an independent associa-
tion with ypN category.
C O M B I N I N G I N D E P E N D E N T R I S K F A C T O R S
The independent risk factors identified in the multi-
variate analysis were combined subsequently to
investigate their potential for risk stratification in the
current study population (Table 4). Patients without
clinically detectable LNM (cN0) and with other
histopathology had the lowest LNM risk (7.7%),
whereas patients with high-grade histopathology had
a high risk regardless of clinical nodal status and
RTD. RTD was of additional value for stratification of
patients who had both clinical nodal involvement
(cN+) and other histopathology (17.8% versus 47.8%
for RTD <10 mm and ≥10 mm, respectively;
P = 0.002).
Based on these data we devised an algorithm
which stratifies patients in three subgroups (low,
intermediate and high risk) according to risk of resid-
ual LNM (Figure 1). LNM risk was 7.7%, 17.8% and
51.6% for the low, intermediate and high-risk cate-
gories, respectively (P < 0.001; Figure 2).
R O L E O F Y P T C A T E G O R Y
The ypT category did not reach statistical significance
or a statistical trend in this study. In a subgroup
NoNo
Low risk
High risk
“High grade”
histopathology?
Intermediate risk
<10 mmResidual tumour
diameter
Yes
Yes
Clinically detected
LNM (cN+)?
≥10 mm
Figure 1. Flowchart depicting
algorithm for risk stratification.
LNM, lymph node metastases;
cN, clinical nodal category.
60.0%
50.0%
40.0%
30.0%
20.0%
10.0% 7.7%
17.8%
51.6%
High riskLow risk Intermediate risk
N = 65 N = 101 N = 31
0.0%
R
is
k 
of
 re
sid
ua
l L
NM
Figure 2. Risk of residual lymph node metastases (LNM) based on
the flowchart algorithm* (n = 197^). *Risk factors are: clinical
nodal involvement (cN+), residual tumour diameter ≥10 mm and
high-grade histopathology (including poorly differentiated and
undifferentiated carcinoma). ^Cases with at least one missing value
(n = 13) were excluded.
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analysis of patients with a ypT2 tumour (n = 88), the
algorithm described in the previous paragraph was
able to stratify patients adequately according to LNM
risk (7.7%, 14.7% and 50.0% for patients in the low,
intermediate and high-risk categories, respectively;
P < 0.001). For patients with a ypT0-1 tumour this
was 7.7%, 19.4% and 66.7% (P = 0.024). Patients
with a pathological complete response of the primary
tumour (ypT0) had residual nodal disease in 10.3%
and 20.8% of cases depending on clinical nodal sta-
tus (cN0 and cN+ respectively; P = 0.231).
Discussion
In this study including 210 TME specimens of consec-
utive rectal cancer patients with ypT0-2 tumours after
CRT, we showed that clinical nodal involvement
(cN+), high-grade histopathology (i.e. poorly differenti-
ated or undifferentiated carcinoma) and RTD of
≥10 mm are strong independent risk factors for resid-
ual LNM. We devised an algorithm based on these risk
factors, which stratifies patients adequately according
to risk of residual nodal disease in the current popula-
tion. Moreover, we showed that the predictive value of
this algorithm was independent of pathological
tumour category after neoadjuvant treatment (ypT).
Clinically suspected nodal disease was the strongest
independent risk factor for residual LNM at
histopathological examination. Residual LNM risk in
cN+ patients was 24.6%, which explains why clinical
trials investigating feasibility of local excision after
CRT generally exclude patients with clinical evidence
of nodal involvement.23,24 However, LNM rate was
10.4% in the cN0 group, showing that clinical imag-
ing is relatively inaccurate for the prediction of nodal
disease.25,26
RTD was useful only in cN+ patients. RTD can be
regarded as a footprint of the original tumour which
reflects its level of therapy resistance, similar to TRG.
TRG correlates with the therapy resistance of associ-
ated LNM, with similar levels of regression in both
the primary tumour and the lymph nodes.27 The pre-
dictive value of RTD is based most probably on the
same principle. In the case of a local excision,
the advantage of RTD over TRG is that it is based on
the amount of microscopically detectable residual
tumour in the specimen, whereas for TRG an esti-
mate of the amount of tumour mass turned fibrosis is
essential.17 Estimates of TRG are therefore not feasible
after local excision, as an important part of the
fibrotic areas are located in the mesorectal fat and
therefore missing in the specimen.
High-grade histopathology was a strong and inde-
pendent risk factor associated with a 62.5% risk of
LNM, although it was found in relatively few cases in
the current population. This result is in accordance
with previous series on early colorectal cancer.20,28
Differentiation grade was determined in the CRT-trea-
ted resection specimens, as pretherapy biopsies are
notoriously unreliable for grading purposes with sub-
stantial variation between grade of differentiation
determined on biopsy and after definitive surgery,29
due probably to sampling error. Indeed, WHO criteria
define type and grade according to the relative domi-
nance of specific tumour components (e.g. more or
less than 50% gland formation; more or less than
50% mucin production),16 and a superficial biopsy
may miss a relevant component entirely. Conversely,
CRT may induce significant morphological changes,
including disappearance of tumour tissue with fibrosis
and mucinous degeneration.30 This may change the
proportion of various tumour components and may
yield a different grade than would have been the case
without neoadjuvant treatment. However, as both
the primary tumour and LNM have been reported to
undergo similar levels of regression with loss of the
most susceptible tumour components,27 it may be
hypothesized that the post-CRT morphology is likely
to reflect the risk of residual LNM most adequately.
The relatively low number of examined lymph
nodes is a limitation to this study, as a minimum of
12 nodes is generally recommended for adequate
nodal staging.31 However, lymph node yield is known
to decrease after chemoradiation, and the median
number of seven nodes found in this study is compa-
rable with results described in several previous
reports after neoadjuvant therapy.32–35 Lymph node
yield was not associated with nodal positivity in the
current population. However, this may be related to a
lack of statistical power to detect a correlation, as
previous studies found the LNM rate to increase with
the number of examined lymph nodes.33,34
Furthermore, the multicentre design of this study
implies some inherent variations between centres in
distribution of patient and treatment characteristics,
such as gender, clinical stage and type of chemother-
apy. However, the included rectal cancer patients
constitute an adequate reflection of the case-mix
encountered in clinical practice, and results may
therefore be applicable widely. Moreover, the multi-
variate analysis showed the identified risk factors to
be independent of centre.
However, the current results cannot be extrapo-
lated directly to a local excision setting. For example,
© 2016 John Wiley & Sons Ltd, Histopathology
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pathological tumour category may be underestimated
in local excision specimens due to the often discontin-
uous nature of residual tumour foci after neoadjuvant
CRT, as some residual tumour cells may remain
undetected in the mesorectal fibrosis. Furthermore,
our study is based on a relatively unfavourable popu-
lation, including many patients with unfavourable
clinical characteristics such as T4 tumours or clinical
N2 disease, and many of them would in practice
never be considered for rectal preservation. Therefore,
our results are hypothesis-generating, and the identi-
fied risk factors, as well as their association with local
recurrence risk, should be investigated and validated
in appropriately selected populations.
In summary, this study shows that clinical nodal
involvement, high-grade histopathology and RTD are
strong and independent predictors for the presence of
residual nodal disease in rectal cancer patients with
ypT0-2 tumours after neoadjuvant CRT. An algo-
rithm combining these risk factors to stratify patients
according to low, intermediate or high LNM risk was
shown to be accurate, regardless of ypT category. If
validated in appropriately selected populations these
factors may contribute to an effective stratification of
patients according to risk of LNM and local recur-
rence. This may improve decision-making regarding
local or radical surgery, and may help to save
selected patients from undergoing an unnecessary,
yet potentially harmful, TME while ensuring oncolog-
ical safety.
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